Skip to main content
HKMPY logo

Hikma Pharmaceuticals PLC (HKMPY) Stock Price & Analysis

Hikma Pharmaceuticals PLC (HKMPY) — price $47.75 (0.00%), as of the Nov 19, 2026 trading session; market cap $4.94B.

Educational signal · not a buy or sell recommendation · How to read this

$47.75 $0.00 (0.00%) Market Cap $4.94B

Hikma Pharmaceuticals PLC · HKMPY

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products across various therapeutic areas. The company operates through Injectables, Generics, and Branded segments, serving markets in the United States, the Middle East, North Africa, Europe, and the United Kingdom.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • SUPN · Supernus Pharmaceuticals, Inc. · 74 /100
  • LNTH · Lantheus Holdings, Inc. · 96 /100
  • BHC · Bausch Health Companies Inc. · 30 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$47.75
Change on the day0.00%
52-week range$31.80 – $47.75
Market capitalisation$4.94B—
Price / earnings (trailing)12.35
Shares traded on the day103

Price & events

Other perspectives

Council score for Hikma Pharmaceuticals (HKMPY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

1 lens, 1 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Weak
ROE Moderate
Gross Margin Moderate

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Hikma Pharmaceuticals (HKMPY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Hikma Pharmaceuticals PLC (HKMPY) is the company analyzed here. It employs 9,400 people and is led by Said Samih Taleb Darwazah. In Q2 FY2026 it reported revenue of $1.73B and net income of $223M. The market values it at $4.94B.

2 · Latest results

What do the latest results show for Hikma Pharmaceuticals (HKMPY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $1.73B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$1.73B$223M$2.04 (diluted)
Q4 FY2025$1.68B$163M$1.48 (diluted)
Q2 FY2025$1.66B$238M$2.14 (diluted)
Q4 FY2024$1.56B$132M$1.18 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Hikma Pharmaceuticals (HKMPY)?

Short answer · as of

The distress and quality screens read Altman Z 2.74 · Piotroski F 6. Trailing ratios: ROE 15.0% · ROA 6.6% · current ratio 1.98 · earnings yield 8.2% · free-cash-flow yield 3.2%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held HKMPY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported HKMPY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Hikma Pharmaceuticals (HKMPY)?

Read these with our analysis →

Hikma Pharmaceuticals Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the HKMPY research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is HKMPY a good stock to buy?

Stock Expert AI does not rate HKMPY buy, sell or hold. Hikma Pharmaceuticals PLC has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the HKMPY stock price today?

The last price recorded for Hikma Pharmaceuticals PLC (HKMPY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for HKMPY?

Hikma Pharmaceuticals PLC faces several risks, including pricing pressures in the generic drug market, competition from other generic drug manufacturers, regulatory changes and compliance issues, and currency fluctuations. The company's dependence on key products and markets also poses a risk. Investors should carefully consider these risks before investing in HKMPY stock.

What are the key factors to evaluate for HKMPY?

Evaluate HKMPY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Successful launches of new medications can drive revenue growth and increase profitability. Not financial advice.

How frequently does HKMPY data refresh on this page?

HKMPY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven HKMPY's recent stock price performance?

Hikma Pharmaceuticals PLC (HKMPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across generics, injectables, and branded products. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider HKMPY overvalued or undervalued right now?

The trailing P/E of Hikma Pharmaceuticals PLC (HKMPY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research HKMPY before investing?

Before investing in Hikma Pharmaceuticals PLC (HKMPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.